The potential benefits of stem cell-based technology in Factorfive anti-aging skin care has parent company Xytogen Biotech Inc. in a bit of a bind, forcing it to keep the capability of products under wraps to avoid drug claims.
Factorfive’s Stem Cell-Based Skin Care Benefits Exceed Promotional Claims – CEO
Xytogen Biotech’s Factorfive stem cell-based skin care delivers benefits that are greater than the company claims, says founder and CEO John Aylworth. Available mostly through clinicians’ offices, the formulas are based on a proprietary process that triggers stem cells to send out growth factor signals, which are captured in a ‘conditioned media’ and used as the basis for products.
More from New Products
• By
RoC launches RoC 35 Protocol, a five-product regimen backed by the brand’s largest clinical assessment yet, showing 200 subjects saw significant improvement in ‘key parameters’ of skin aging.
• By
Church & Dwight Co. Inc. will launch a new body acne patch under its Hero Mighty Patch range, a light dry shampoo formula for Batiste and three new initiatives for vitafusion gummies, the firm reported during its Analyst Day 31 January.
• By
Eucerin Radiant Tone Collection comprises five products centered on the brand’s wildly popular ingredient Thiamidol, currently the most effective inhibitor of human tyrosinase, an enzyme that contributes to skin hyperpigmentation.
• By
Target Corp. expands affordable wellness offerings in 2025 with 2,000 new items, including personal care and beauty. Separately, Coty Inc.’s Rimmel London brand launches Wonder Bond Bonding Serum Mascara and Covergirl introduces Lash Blast Supercloud Mascara featuring an ‘air-whipped’ emulsion formula; US Beauty Launch News.
More from Leadership
• By
Parking and security at the FDA’s White Oak headquarters were strained from the influx of employees who had to report to work in person on 17 March.
• By
The Health and Human Services Department's decision to eliminate the Richardson Waiver may be a blow for transparency, but will not completely eliminate scrutiny of regulations, experts said.
• By
Industry likely wants Grace Graham to take the FDA’s top policy and legislative role, but she may be passed over for someone more tied to HHS Secretary Robert F. Kennedy Jr.’s interests.